Introduction {#Sec1}
============

Metabolic syndrome (MS) has attracted increased attention due to its significant impact on cardiovascular diseases (CVD) and diabetes \[[@CR1]--[@CR3]\]. In the past few decades, different definitions of MS have been proposed by several organizations. For example, the World Health Organization (WHO) \[[@CR4]\], the US National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) \[[@CR5]\], and International Diabetes Federation (IDF) \[[@CR6]\] have put forward their interpretations. Before long, the American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) revised the ATPIII definition \[[@CR7]\]. However, there is no consensus on the definition of MS worldwide. Studies revealed that the impact of different definitions of MS on the risk of future CVD and diabetes is discrepant \[[@CR8], [@CR9]\].

In China, the Joint Committee for Developing Chinese Guidelines (JCDCG) suggested a Chinese definition for MS \[[@CR10]\]. The JCDCG version has been applied as a useful tool to investigate MS and predict the risk of CVD in the Chinese population \[[@CR11]--[@CR14]\]. A community-based cohort study in southeast China revealed that only MS defined by the JCDCG, not those proposed by IDF and ATPIII, was associated with an increased risk of CVD events in Chinese women \[[@CR15]\]. However, in China, different regions have their own lifestyles, and differences are especially between the south and the north, which may influence the metabolic status \[[@CR16]--[@CR18]\]. Accordingly, some studies had a different conclusion that the JCDCG's definition was not appropriate for defining MS and predicting acute coronary syndrome among Chinese people \[[@CR19], [@CR20]\]. Therefore, there is an urgent need to determine whether the JCDCG definition is more appropriate than other definitions used effectively in the world, especially in northwestern Chinese people.

In order to provide solid proof for the determination, we conducted a population-based study by using data from the China National Diabetes and Metabolic Disorders Study (CNDMDS) in Shaanxi province, northwest China, and evaluated the JCDCG, revised ATPIII (Definition proposed by AHA/NHLBI), and IDF for the diagnosis of MS. We also investigated the agreement between the JCDCG definition and the two aforementioned definitions that are widely used.

Methods {#Sec2}
=======

Participants {#Sec3}
------------

This study was a subsection of the second stage of the CNDMDS, a representative cross-sectional cohort of Chinese adults from June 2007 to May 2008. The details of the CNDMDS can be found in a previous study \[[@CR21]\]. In brief, a multistage, stratified sampling method was used to select a representative cohort aged ≥ 20 years from the general population in Shaanxi province (more details can be found in our previous study) \[[@CR22]\].

A total of 3930 individuals who had lived in their residence for ≥ 5 years were randomly chosen and invited to participate in the study. Of them, 3298 individuals completed the survey and examination (overall response rate, 83.9%). After excluding 55 individuals who had missing data for waist circumference (WC), fasting serum glucose levels, 2-h postprandial glucose levels, serum triglyceride levels, serum high-density lipoprotein cholesterol (HDL-C) levels, or blood pressure (BP), we finally included 3243 subjects with complete data in the study.

Compliance with Ethics Guidelines {#Sec4}
---------------------------------

The Institutional Review Boards of Xijing Hospital, Fourth Military Medical University approved this study. Written informed consent was obtained from each participant prior to data collection.

Measurements {#Sec5}
------------

A standard questionnaire was administered by well-trained staff to obtain information including the demographic characteristics, lifestyle risk factors, personal medical history, family history of diseases, educational level, cigarette smoking, alcohol drinking, and physical activity. Height and body weight were measured in an upright position, to the nearest 0.5 cm and 0.1 kg, respectively. The WC measurements were taken at the end of a normal exhalation and were measured to the nearest 0.1 cm from the midpoint between the lower borders of the rib cage and the anterior superior iliac spine. Body mass index (BMI) was calculated as weight in kilograms divided by the square of height in meters. The mean of two BP measurements was used. Readings of systolic BP and diastolic BP were taken 5 min apart in the resting state.

An oral glucose-tolerance test was performed for each subject. All participants were required to fast for at least 8 h beforehand, the participants without history of diabetes were subject to a 75-g oral glucose tolerance test, and those with a history of diabetes were given a bread meal test for safety reasons. Vein blood samples were drawn at 0, 30, and 120 min after glucose or carbohydrate load. The plasma glucose (PG) levels including fasting PG and 2 h PG (2hPG) were measured. Furthermore, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol (TC), and triglyceride (TG) levels in the serum were measured using commercially available reagents at the clinical biochemical laboratory, Xijing Hospital, Xi'an, China.

Diagnosing Standard {#Sec6}
-------------------

According to the JCDCG, MS is defined if there are more than three of the following abnormalities: (1) Central obesity (WC \> 90 cm for men and \> 85 cm for women); (2) Elevated triglyceride level (≥ 1.7 mmol/L) or receipt of specific treatment for this lipid abnormality; (3) Reduced HDL-C level (\< 1.04 mmol/l) or specific treatment for this lipid abnormality; (4) Elevated BP (≥ 130/85 mmHg or current treatment for hypertension) or previously diagnosed hypertension; (5) Elevated PG level (fasting PG ≥ 6.1 mmol/L or 2 h postprandial PG ≥ 7.8 mmol/L) or previously diagnosed diabetes mellitus \[[@CR10]\].

The revised ATPIII definition was defined as three or more of the following abnormalities: (1) WC of 90 cm for men of Asian origin and 80 cm for women of Asian origin; (2) Triglyceride level of 1.7 mmol/L or receipt of drug treatment for elevated triglyceride levels; (3) HDL-C level of 1.03 mmol/L in men and 1.29 mmol/L in women or receipt of drug treatment for reduced HDL-cholesterol level; (4) High blood pressure of 130/85 mmHg or receipt of drug treatment for hypertension; (5) Impaired fasting PG level of 5.6 mmol/L or receipt of drug treatment for elevated glucose level \[[@CR7]\].

According to the IDF definition, MS is defined as central obesity (WC ≥ 90 cm for Chinese men and ≥ 80 cm for Chinese women) along with two or more of the following abnormalities: (1) Triglyceride level of 1.7 mmol/L or receipt of specific treatment for this lipid abnormality; (2) HDL-C level of 1.03 mmol/L in men and 1.29 mmol/L in women or receipt of specific treatment for this lipid abnormality; (3) BP of 130/85 mmHg or receipt of treatment of previously diagnosed hypertension; (4) Fasting PG level of 5.6 mmol/L or previously diagnosed type 2 diabetes \[[@CR6]\].

Statistical Analysis {#Sec7}
--------------------

Continuous variables were expressed as the mean ± standard deviation, and categorical variables are presented as proportions. *P* values \< 0.05 were considered statistically significant. To compare continuous variables between groups, a *t* test was used. To compare categorical variables between groups, the chi-square test was used. Linear trends for sex- and age-specific mean or proportion were tested using analysis of variance linear test (polynomial) or chi-square test for linear-by-linear association, respectively. A binary logistic regression analysis was adopted to compare the prevalence of MS between genders after adjusting for age. Agreement between different MS definitions was evaluated by the*κ* value (poor, *κ* ≤ 0.20; fair, *κ* = 0.21--0.40; moderate, *κ* = 0.41--0.60; substantial, *κ* = 0.61--0.80; very good, *κ* \> 0.80) \[[@CR23]\]. As our study was conducted in 2007--2008, the percentage values of MS prevalence were standardized by the direct method according to the Chinese population structure in 2007 \[[@CR24]\].

A database was established using EpiData 3.1 software. Statistical analyses were carried out using the International Business Machines Corporation Statistical Package of Social Science for Windows version 22.0 (IBM Corp., Armonk, NY, USA).

Results {#Sec8}
=======

Characteristics of Study Population {#Sec9}
-----------------------------------

The baseline characteristics of the study subjects are shown in Table [1](#Tab1){ref-type="table"}. This study included 3243 individuals (1359 men, 1884 women; men/women 0.721; age of men 44.3 ± 14.0 years, women 44.1 ± 13.7 years), with a mean BMI of 23.9 kg/m^2^. Men had a significantly higher BMI, WC, triglyceride level, LDL-C level, education level, and proportion of alcohol drinking and cigarette smoking, whereas women had significantly higher HDL-C levels. The mean level of HDL-C was higher in women than in men. The systolic BP, diastolic BP, TC, fasting PG, 2hPG, and proportion of subjects who performed physical activity showed no significant differences between the two genders.Table 1Characteristics of the study populationVariablesTotal (*n* = 3243)Men (*n* = 1359)Women (*n* = 1884)*P* valueAge (years)44.2 ± 13.844.3 ± 14.044.1 ± 13.70.615Educational level (*n* %) Elementary school or below730 (22.5)209 (15.4)521 (27.7)\< 0.001 Middle school1601 (49.4)710 (52.2)891 (47.3)0.007 Collage or above912 (28.1)442 (32.5)470 (24.9)\< 0.001Physical activity (*n* %)1224 (37.7)534 (39.3)690 (36.6)0.139Alcohol drinking (*n* %)801 (24.7)694 (51.1)107 (5.7)\< 0.001Cigarette smoking (*n* %)770 (23.7)745 (54.8)25 (1.3)\< 0.001BMI (kg/m^2^)23.9 ± 1.4024.3 ± 4.3723.6 ± 3.88\< 0.001WC (cm)81.9 ± 10.285.8 ± 9.7279.1 ± 9.50\< 0.001SBP (mmHg)120.9 ± 20.2121.3 ± 20.7120.5 ± 19.90.241DBP (mmHg)76.7 ± 11.676.6 ± 11.876.7 ± 11.50.836TC (mmol/L)4.71 ± 1.034.72 ± 1.024.70 ± 1.030.570TG (mmol/L)1.56 ± 1.281.75 ± 1.501.43 ± 1.07\< 0.001HDL-C (mmol/L)1.29 ± 0.311.21 ± 0.281.35 ± 0.31\< 0.001LDL-C (mmol/L)2.64 ± 0.802.68 ± 0.762.61 ± 0.820.020FPG (mmol/L)5.23 ± 1.405.25 ± 1.435.21 ± 1.390.2882hPG (mmol/L)6.52 ± 3.296.44 ± 3.236.58 ± 3.320.244*P* values are from *t* tests between genders*BMI* body mass index, *WC* waist circumference, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *TC* total cholesterol, *TG* triglycerides, *HDL-C* high-density lipoprotein cholesterol, *LDL-C* low-density lipoprotein cholesterol, *FPG* fasting plasma glucose, *2hPG* 2-h plasma glucose

Standardized Prevalence of MS {#Sec10}
-----------------------------

The standardized MS prevalence rates of the study population as per the JCDCG-MS, revised ATPIII-MS, and IDF-MS were 22.4%, 29.4%, and 24.9%, respectively (Table [2](#Tab2){ref-type="table"}). The prevalence rates of JCDCG-MS, revised ATPIII-MS, and IDF-MS were 27.0%, 27.9%, and 22.7% in men and 18.0%, 30.8%, and 27.0% in women, respectively. As compared to men, more women had MS according to the IDF definition (27.9% vs. 30.8%, *P *= 0.012) and revised ATPIII definition (22.7% vs. 27.0%, *P *\< 0.001). In contrast, more men than women were diagnosed with MS as per the JCDCG definition (27.0% vs. 18.0%, *P *\< 0.001). Linear trends in the prevalence of MS showed a significant increase with age in both genders according to all three definitions (Table [2](#Tab2){ref-type="table"}).Table 2Standardized proportion (95% confidence interval) of metabolic syndrome using the JCDCG, revised ATPIII, and IDF definitionJCDCG-MSRevised ATPIII-MSIDF-MSOverall22.4 (21.0--23.8)^a^29.4 (27.8--31.0)^a^24.9 (23.4--26.4)^a^Men27.0 (24.6--29.4)^b^27.9 (25.5--30.3)^b^22.7 (20.5--24.9)^b^Women18.0 (16.3--19.7)^b^30.8 (28.7--32.9)^b^27.0 (25.0--29.0)^b^*P* ^c^\< 0.0010.012\< 0.001Men age (years) 20--2912.9 (8.6--17.2)12.4 (8.2--16.6)10.3 (6.4--14.2) 30--3928.5 (23.6--33.4)31.5 (26.5--36.6)27.0 (22.2--31.8) 40--4933.8 (28.5--39.1)35.2 (29.9--40.5)28.4 (23.4--33.4) 50--5939.4 (33.6--45.2)38.5 (32.7--44.3)26.6 (21.3--31.9) 60--6942.6 (34.7--50.5)40.6 (32.7--48.5)32.6 (25.1--40.1) ≥ 7026.7 (16.5--37.0)26.7 (16.5--37.0)24.2 (14.3--34.1) *P*^d^\< 0.001\< 0.001\< 0.001Women age (years) 20--293.2 (1.2--5.2)8.7 (5.6--11.9)7.7 (4.7--10.7) 30--396.7 (4.4--9.0)16.7 (13.3--21.2)13.8 (10.6--17.0) 40--4917.8 (14.4--21.2)37.1 (32.8--41.5)29.9 (25.8--34.0) 50--5934.8 (30.0--39.6)54.1 (49.1--59.1)49.2 (44.2--54.2) 60--6940.4 (33.5--47.3)57.9 (51.0--64.8)49.8 (42.8--56.8) ≥ 7043.1 (32.1--54.1)49.3 (38.2--60.4)49.3 (38.2--60.4) *P*^d^\< 0.001\< 0.001\< 0.001*JCDCG* Joint Committee for Developing Chinese Guidelines, *ATPIII* Adult Treatment Panel III, *IDF* International Diabetes Federation^a^Age- and sex-adjusted percentages^b^Age-adjusted percentages for men or women. The percentage values were standardized by the direct method according to the Chinese population structure in 2007^c^Adjusted for age using binary logistic analysis^d^*P* value for linear trend from the chi-square test for linear-by-linear association

Crude Prevalence of Metabolic Abnormalities According to JCDCG, Revised ATPIII, and IDF Criteria {#Sec11}
------------------------------------------------------------------------------------------------

In men, except for the elevated PG and central obesity, the prevalence of the other metabolic abnormalities according to the revised ATPIII (IDF) criteria was similar in either MS group or non-MS group. About 74.0% of JCDCG-MS and 81% of ATPIII-MS were defined as MS by the IDF definition, 91.0% of JCDCG-MS and all the IDF-MS were defined as MS by the revised ATPIII definition, and 87.9% of ATPIII-MS and 88.3% of IDF-MS were defined as MS by the JCDCG definition (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Crude prevalence of metabolic abnormalities according to JCDCG, revised ATPIII, and IDF criteria in men

In women, according to JCDCG criteria, the crude prevalence of elevated TG, elevated BP, elevated PG, central obesity, and reduced HDL-C was higher in JCDCG-MS subjects. In addition, the prevalence rates of the metabolic abnormalities mentioned above were not lower in non-MS subjects defined by the JCDCG definition than the non-MS subjects defined by the other two definitions. According to the JCDCG definition, 54.6% of ATPIII-MS and 56.0% of IDF-MS were defined as MS; 14.4% and 17.0% of non-MS subjects according to the JCDCG definition were defined as MS by the IDF definition and revised ATPIII definition, respectively (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2Crude prevalence of metabolic abnormalities according to JCDCG, revised ATPIII, and IDF criteria in women

Agreement Between JCDCG, Revised ATPIII, and IDF Criteria for MS Diagnosis {#Sec12}
--------------------------------------------------------------------------

To verify the agreement between the different definitions of MS for both genders, we used the*κ* statistic. A substantial overall agreement (*κ* = 0.712) was observed between the JCDCG and revised ATPIII definitions, and a moderate overall agreement (*κ* = 0.648) was observed between the JCDCG and IDF definitions (Table [3](#Tab3){ref-type="table"}). When analyzed by gender, very good agreement (*κ* = 0.863) was observed between the JCDCG and revised ATPIII definitions for men, but only a moderate agreement (*κ* = 0.599) was observed for women. A substantial agreement was found for both genders between the JCDCG and IDF definitions (overall, *κ* = 0.648; men, *κ* = 0.741; women, *κ* = 0.601).Table 3Agreement of the JCDCG with the revised ATPIII and IDF criteria for the diagnosis of MSJCDCG*Κ* value+−TotalRevised ATPIII Overall  +74833010780.712  −5921062165  Total80724363243 Men  +386434290.863  −38892930  Total4249351359 Women  +3622876490.599  −2112141235  Total38315011884IDF Overall  +6352739080.648  −17121642335  Total80624373243 Men  +3121114230.741  −32904936  Total34410151359 Women  +240232630.601  −1809761156  Total4209991419Agreement between the different MS definitions was evaluated by the *κ* statistic (poor, *κ* ≤ 0.20; fair, *κ* = 0.21--0.40; moderate, *κ* = 0.41--0.60; substantial, *κ* = 0.61--0.80; very good, *κ* \> 0.80)*JCDCG* Joint Committee for Developing Chinese Guidelines, *ATPIII* Adult Treatment Panel III, *IDF* International Diabetes Federation

Discussion {#Sec13}
==========

We conducted a population-based study in Shaanxi province, northwest China, to compare the JCDCG definition of MS with the IDF and the revised ATPIII definitions. We found that the agreement between the JCDCG definition and the revised ATPIII or the IDF definitions was not good enough, especially in northwestern Chinese women. JCDCG only recognized 56.0% of IDF-MS and 54.6% of revised ATP-MS; also, there were still 14.4% of IDF-MS and 17.0% of revised ATP-MS defined as non-MS according to JCDCG. These results indicated that the JCDCG definition may underestimate the prevalence of MS in women compared with the other two definitions. Hence, we should consider the gender difference and further verify the reliability of the JCDCG definition in assessing MS in northwestern Chinese women.

Our results showed that 22.4% of Shaanxi adults met the MS criteria according to the JCDCG definition, which is slightly higher than the national level. In a nationwide study performed in 2007--2008, which enrolled 46,024 participants, the prevalence of MS according to the JCDCG definition was 21.9% \[[@CR13]\]. Varied prevalence was observed in different regions of China. A community-based study conducted in Shanghai, southeast China, revealed that 24.4% of study subjects met the MS definition of JCDCG. The varied prevalence of MS between northern and southern areas of China may be partially explained by different lifestyles, e.g., physical exercise, education level, and economic status \[[@CR16], [@CR25]\]. In addition to these factors, studies have also revealed that the MS prevalence depends on the definition used \[[@CR26]--[@CR28]\]. The community-based study in Shanghai also revealed moderate to good agreement between the JCDCG definition with the IDF and ATPIII definition, with kappa value between 0.635 and 0.825 in both women and men. In spite of all these studies, there was lack of data evaluating JCDCG compared with other definitions in northern Chinese populations. As we acknowledged, we first revealed the agreement of the JCDCG definition with other definitions in northwestern Chinese people.

In the current study, the agreement between the JCDCG definition and the other two was not very good in women. As we observed JCDCG only recognized 56.0% of IDF-MS and 54.6% of revised ATP-MS; also, there were still 14.4% of IDF-MS and 17.0% of revised ATP-MS defined as non-MS according to JCDCG. Furthermore, according to JCDCG criteria of the metabolic abnormalities, the crude prevalence of the five metabolic abnormalities was higher in both MS and non-MS subjects by JCDCG than the subjects defined by revised ATPIII and IDF definitions. These results all proved the poor agreement between JCDCG and the other two definitions in northwestern Chinese women. Comparison of the three criteria of MS shows that the different cutoffs of central obesity (waist circumference, 80 vs 85 cm), reduced HDL-C (1.04 vs. 1.29 mmol/l), and hyperglycemia (FPG 5.6 mmol/l vs. FPG 6.1 mmol/l, 2hPG 7.8 mmol/l) may lead to the different prevalence. Among those above, the most important criteria of metabolic syndrome should be based upon the visceral adiposity which controls the micro-inflammation, adiponectin, and adipocytokines that induce insulin resistance. The waist circumference of 85 cm for women was derived from visceral fat area (VFA) measured by magnetic resonance imaging in a southeastern Chinese population in Shanghai. Similarly, the cutoff point of waist circumference was also 85 cm in Japanese women, and it was determined by the visceral level area obtained by CT scan \[[@CR29]\]. Recently an intervention trial based on a large population confirmed the validity of this criterion \[[@CR30]\]. But it remains unclear whether the waist circumference of 85 cm for women is adapted to northwestern Chinese women; a prospective study should be conducted to verify this. Previous study has revealed that agreement between the JCDCG definition and other definitions (the WHO, IDF, and ATPIII definitions) was moderate to good in southeastern Chinese women \[[@CR15]\]. With such different results in different regions, we should be cautious when using the JCDCG definition, and the JCDCG definition need to be verified by prospective study in northwestern Chinese women. So far, no study has observed such differences according to JCDCG and other widely used definitions in northwestern Chinese women.

In men, the agreement between JCDCG, IDF, and revised ATPIII definition was good. The prevalence of MS defined by IDF was slightly lower than the prevalence of MS defined by JCDCG and revised ATPIII definitions, possibly because central obesity has been regarded as a requisite criterion of the IDF definition. However, the prevalence of MS defined by JCDCG and revised ATPIII was close (JCDCG-MS: 27.0%, revised ATPIII-MS: 27.9%), because the only difference between the two definition is the cutoff of elevated PG. The prevalence rates of JCDCG-MS we observed in our present study were similar to the nationwide study (27.0% vs. 25.8%) and the community-based study in Shanghai (27.0% vs. 26.1%) which was mentioned above \[[@CR13], [@CR15]\]. Based on the results above, the agreement between JCDCG and the other two definitions was good in men. It was very different from what we had observed in women for these three definitions.

Despite our important findings, our study has some limitations. First, as it was a cross-sectional study, future prospective studies should be conducted to examine which definition of MS has better predictive power for the risk of CVD and diabetes. Second, as the study was conducted in northwest China, the conclusions from this study may not be generalizable to other areas. Finally, we cannot exclude the possibility of selection bias. For example, the prevalence of MS decreased in the group of subjects aged 70 or older. It may because there were few subjects in this group. There are also strengths in our study: our present study not only observed the prevalence of MS according to JCDCG but also compared JCDCG with the IDF and the revised ATPIII definitions in the northwestern Chinese population. In addition, our study assessed the definitions of MS in men and women separately.

Conclusions {#Sec14}
===========

The agreement of the JCDCG definition with the revised ATPIII and the IDF definitions was insufficient in women. The JCDCG definition may underestimate MS in the northwestern female population when compared with the other two definitions, most likely because of the loose cutoffs of central obesity in women. Therefore, the cutoffs of central obesity in northwestern Chinese women need to be verified, and we should be aware of the difference between the JCDCG definition and the other MS definitions when evaluating MS in northwestern Chinese women. Prospective studies may be needed to prove the capability of the definitions for predicting future cardiovascular disease and diabetes.
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